NO20005386D0 - Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom - Google Patents

Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom

Info

Publication number
NO20005386D0
NO20005386D0 NO20005386A NO20005386A NO20005386D0 NO 20005386 D0 NO20005386 D0 NO 20005386D0 NO 20005386 A NO20005386 A NO 20005386A NO 20005386 A NO20005386 A NO 20005386A NO 20005386 D0 NO20005386 D0 NO 20005386D0
Authority
NO
Norway
Prior art keywords
treatment
bowel syndrome
irritable bowel
nmda antagonists
nmda
Prior art date
Application number
NO20005386A
Other languages
English (en)
Norwegian (no)
Other versions
NO20005386L (no
Inventor
Aziz Asghar
Jose Luis Cabero
Andrew Dray
Anne King
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SE9801494A external-priority patent/SE9801494D0/xx
Priority claimed from SE9803954A external-priority patent/SE9803954D0/xx
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20005386D0 publication Critical patent/NO20005386D0/no
Publication of NO20005386L publication Critical patent/NO20005386L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/06—Anti-spasmodics, e.g. drugs for colics, esophagic dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20005386A 1998-04-28 2000-10-26 Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom NO20005386L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
SE9801494A SE9801494D0 (sv) 1998-04-28 1998-04-28 Novel use
SE9803954A SE9803954D0 (sv) 1998-11-18 1998-11-18 Novel use
PCT/SE1999/000702 WO1999055323A1 (en) 1998-04-28 1999-04-28 Use of nmda antagonists for treatment of irritable bowel syndrome

Publications (2)

Publication Number Publication Date
NO20005386D0 true NO20005386D0 (no) 2000-10-26
NO20005386L NO20005386L (no) 2000-10-26

Family

ID=26663287

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005386A NO20005386L (no) 1998-04-28 2000-10-26 Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom

Country Status (21)

Country Link
EP (1) EP1073431B1 (ko)
JP (1) JP2002512956A (ko)
KR (1) KR100569777B1 (ko)
CN (1) CN1200702C (ko)
AR (1) AR016212A1 (ko)
AT (1) ATE270545T1 (ko)
AU (1) AU760783B2 (ko)
BR (1) BR9909971A (ko)
CA (1) CA2329328A1 (ko)
DE (1) DE69918541T2 (ko)
DK (1) DK1073431T3 (ko)
ES (1) ES2221753T3 (ko)
HK (1) HK1033876A1 (ko)
IL (1) IL138919A0 (ko)
MY (1) MY121063A (ko)
NO (1) NO20005386L (ko)
NZ (1) NZ507436A (ko)
PT (1) PT1073431E (ko)
SA (1) SA99200482B1 (ko)
TW (1) TW570793B (ko)
WO (1) WO1999055323A1 (ko)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030119916A1 (en) * 2000-03-01 2003-06-26 David Fowler Treatment of functional gastrointestinal disorders
TW593223B (en) * 2000-06-20 2004-06-21 Merz Pharma Gmbh & Co Kgaa 1-amino-alkylcyclohexanes as 5-HT3 and neuronal nicotinic receptor antagonists
JP2003081872A (ja) * 2001-09-13 2003-03-19 Nippon Oruganon Kk 掻痒治療薬
EP1603544B1 (en) * 2003-03-14 2007-10-10 AGI Therapeutics Research Limited Treatment of intestinal conditions with n-2,3,3-tetramethylbicyclo 2.2.1 heptan-2-amine
WO2004084889A1 (en) * 2003-03-28 2004-10-07 Pfizer Inc. Use of protein kinase c inhibitor for suppressing sustained slow postsynaptic excitation (sspe) of enteric neurons
FR2865133B1 (fr) * 2004-01-19 2008-01-18 Rytek Compositions pour le traitement de pathologies digestives
CA3105834A1 (en) * 2018-07-06 2020-01-09 Algernon Pharmaceuticals Inc. Compounds for treatment of inflammatory bowel disease and methods thereof
KR102211282B1 (ko) 2019-11-20 2021-02-03 (주)파이브텍 데이터 라우팅 방법 및 이를 지원하는 스위치

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL84305A (en) * 1987-02-06 1992-01-15 Fisons Corp 2-aminoacetamide derivatives
GB9518027D0 (en) * 1995-09-05 1995-11-08 Wellcome Found Pharmacologically active compound
AUPN605795A0 (en) * 1995-10-19 1995-11-09 F.H. Faulding & Co. Limited Analgesic pharmaceutical composition

Also Published As

Publication number Publication date
CN1307471A (zh) 2001-08-08
AU760783B2 (en) 2003-05-22
JP2002512956A (ja) 2002-05-08
EP1073431A1 (en) 2001-02-07
TW570793B (en) 2004-01-11
PT1073431E (pt) 2004-10-29
CA2329328A1 (en) 1999-11-04
HK1033876A1 (en) 2001-09-28
ATE270545T1 (de) 2004-07-15
DE69918541D1 (de) 2004-08-12
MY121063A (en) 2005-12-30
NZ507436A (en) 2003-09-26
WO1999055323A1 (en) 1999-11-04
AR016212A1 (es) 2001-06-20
SA99200482B1 (ar) 2006-06-27
DE69918541T2 (de) 2005-08-18
ES2221753T3 (es) 2005-01-01
CN1200702C (zh) 2005-05-11
DK1073431T3 (da) 2004-10-04
IL138919A0 (en) 2001-11-25
NO20005386L (no) 2000-10-26
EP1073431B1 (en) 2004-07-07
KR100569777B1 (ko) 2006-04-11
BR9909971A (pt) 2000-12-26
AU4302499A (en) 1999-11-16
KR20010043077A (ko) 2001-05-25

Similar Documents

Publication Publication Date Title
NO20014379L (no) Anvendelse av Xenon for behandling av Neurointoksikasjoner
FI19992801A (fi) NMDA-reseptorin 1-aminoalkyylisykloheksaaniantagonisteja
NO20030213D0 (no) Anvendelse av D2/D3 reseptor-agonister for behandling av fibromyalgi
NO20005386D0 (no) Anvendelse av NMDA-antagonister for behandling av irritabel tarmsyndrom
NO20003454D0 (no) FremgangsmÕte for fremstilling av (-)cis-3-hydroksy-1-metyl-4-
NO20023937L (no) Fremgangsmåte for fremstilling av substituert tiazolidindion
PT964867E (pt) Antagonistas da taquicinima
DK1607090T3 (da) Asimadolin til behandling af irritabel tyktarm (Irritable Bowel Syndrome)
NO20003481D0 (no) FremgangsmÕte for behandling av COPD
NO996432D0 (no) Fremgangsmåte for fremstilling av 4-substituert-1H-indol-3- glykosamider
NO984905D0 (no) FremgangsmÕte for fremstilling av b°rstevarer
NO20012612D0 (no) Isonipecotamider for behandling av integren-formidlede lidelser
NO307859B1 (no) FremgangsmÕte for beregning av varighet av oppkoblinger
NO20014845D0 (no) Anvendelse av arylalkanoylpyridaziner
DE29605731U1 (de) Sanitärkeramik
NO20020328D0 (no) Fremgangsmåte for fremstilling av 4-cyano-2-aminometyltiazol
SI1073431T1 (en) Use of nmda antagonists for treatment of irritable bowel syndrome
NO20003077D0 (no) FremgangsmÕte for fremstilling av klorbenzooksazolen
NO20005856L (no) Anvendelse av 1,1-diokso-perhydro-1,2,4-tiadiaziner
NO20020327D0 (no) Fremgangsmåte for fremstilling av 2-aminometyl-4-cyano-tiazol
NO994557D0 (no) Fremgangsmaate for fremstilling av arylaminotriazolopyridiner
EE03762B1 (et) Protsess NMDA antagonistide valmistamiseks
NO995940D0 (no) Anvendelse av leptin antagonister for behandling av diabetes
NO20002476L (no) FremgangsmÕte for fremstilling av formylimidazoler
TH34294B (th) กระบวนการสำหรับการเตรียมคลอโรเบบโซซาโซล

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application